IL6 and colorectal cancer: Preclinical models have demonstrated that TAMs secrete IL-6, which drives chemoresistance through IL-6R/STAT3 signaling; for example, in colorectal cancer, TAM-derived IL-6 confers resistance to 5-fluorouracil (5-FU) (90).